Filing Flows › Immucell (ICCC) › Q1 2026 › vs Q1 2025
Immucell (ICCC) Q1 2026 vs Q1 2025 (year over year)
Immucell's revenue rose $2.3M (+28%) from $8.1M in Q1 2025 to $10.4M in Q1 2026. Gross margin 45.0% against 41.6% (+3.4 pts).
Immucell, Q1 2026: revenue $10.4M (+28% year over year), operating margin 19.0%, net earnings $1.9M, operating cash flow $3.6M. The chart draws each line against Q1 2025, the increases inside each band.
Margins
| Q1 2026 | Q1 2025 | Change | |
|---|---|---|---|
| Gross margin | 45.0% | 41.6% | +3.4 pts |
| Operating margin | 19.0% | 13.9% | +5.2 pts |
| Net margin | 18.7% | 17.9% | +0.8 pts |
| Free cash flow margin | 32.8% | 15.4% | +17.4 pts |
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $10.4M | $8.1M | $2.3M | +28% |
| Gross profit | $4.7M | $3.4M | $1.3M | +39% |
| Cost of revenue | $5.7M | $4.7M | $987K | +21% |
| Operating profit | $2.0M | $1.1M | $852K | +76% |
| Operating expenses | $2.7M | $2.2M | $452K | +20% |
| Pre-tax earnings | $2.0M | $1.4M | $505K | +35% |
| Research & development | $318K | $757K | −$439K | -58% |
| Sales & marketing | $1.2M | $857K | $376K | +44% |
| General & admin | $1.1M | $623K | $515K | +83% |
| Net earnings | $1.9M | $1.4M | $495K | +34% |
| Income tax | $13K | $2K | $11K | +558% |
| Depreciation & amortization | $531K | $687K | −$155K | -23% |
| Share-based compensation | $138K | $52K | $86K | +164% |
| Working capital & other | $962K | −$612K | $1.6M | — |
| Operating cash flow | $3.6M | $1.6M | $2.0M | +127% |
| Free cash flow (OCF − capex) | $3.4M | $1.2M | $2.2M | +173% |
| Capital expenditures | $177K | $329K | −$152K | -46% |
Questions
How much did Immucell's revenue grow year over year in Q1 2026?
Immucell's revenue rose $2.3M (+28%) from $8.1M in Q1 2025 to $10.4M in Q1 2026. Gross margin 45.0% against 41.6% (+3.4 pts).